Low Incidence of Rejection and De Novo Donor‐Specific Antibody Formation Following COVID ‐19 Vaccination or Infection Among Pediatric Kidney Transplant Recipients
Pediatric Transplantation · 2025
DOI: 10.1111/petr.70084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Transplantation, 2025. Verfasst von Helen Pizzo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Nephrology, Guerin Children's Cedars-Sinai Medical Center, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, COVID-19, Graft Rejection, COVID-19 Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: L.L Foundation For Youth.
Abstract (Originalsprache)
Background
Studies in adults have demonstrated a risk for allograft rejection or development of donor‐specific antibodies (DSA) following SARS‐CoV‐2 vaccination. We examined the incidence of acute rejection and de novo DSA following COVID‐19 vaccination or infection among pediatric kidney transplant patients.
Method
Retrospective analysis of 23 pediatric kidney transplant recipients without prior history of rejection, DSA, or COVID‐19 infection who received the SARS‐CoV‐2 mRNA vaccine. Risk for rejection was evaluated via monitoring of serum creatinine, DSA, and donor‐derived cell‐free DNA per center protocol. Results concerning for rejection prompted allograft biopsy, graded by the Banff classification system.
Results
Eight of 23 (34.8%) received two doses of SARS‐CoV‐2 mRNA vaccine, 15 (65.3%) received three doses. Two (8.7%) had rejection; one with de novo DSA, another without. There was no difference in the number of doses of COVID‐19 vaccine received in those with rejection vs. no rejection ( p = 0.53). 13 (56.5%) developed SARS‐CoV‐2 infection, with no difference in the number of vaccines received between those infected with COVID‐19 vs. those who were not ( p = 0.69). No adjustments were made to the maintenance immunosuppression during SARS‐CoV‐2 infection, and there was no evidence of rejection or DSA formation after infection. Median follow‐up time was 29.9 months (IQR 25.0–33.4 months) after the first vaccine dose.
Conclusion
In our small single‐center cohort, SARS‐CoV‐2 vaccination or infection is unlikely to increase the risk for rejection or de novo DSA in pediatric kidney transplant recipients. Larger prospective studies with a control group are needed to further understand the immune effects of the COVID‐19 vaccine and disease in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Nephrology, Guerin Children's Cedars-Sinai Medical Center, Los Angeles, California, USA.
ORCID-Profile: Helen Pizzo, Dechu Puliyanda
Förderung
- L.L Foundation For Youth
Zitieren
APA
Pizzo, H., Garrison, J., Kirshner, K., & Puliyanda, D. (2025). Low Incidence of Rejection and De Novo Donor‐Specific Antibody Formation Following COVID ‐19 Vaccination or Infection Among Pediatric Kidney Transplant Recipients. Pediatric Transplantation. https://doi.org/10.1111/petr.70084
Vancouver
Pizzo H, Garrison J, Kirshner K, Puliyanda D. Low Incidence of Rejection and De Novo Donor‐Specific Antibody Formation Following COVID ‐19 Vaccination or Infection Among Pediatric Kidney Transplant Recipients. Pediatric Transplantation. 2025. doi:10.1111/petr.70084
BibTeX
@article{Pizzo2025,
author = {Pizzo, Helen and Garrison, Jonathan and Kirshner, Kelly and Puliyanda, Dechu},
title = {Low Incidence of Rejection and De Novo Donor‐Specific Antibody Formation Following COVID ‐19 Vaccination or Infection Among Pediatric Kidney Transplant Recipients},
journal = {Pediatric Transplantation},
year = {2025},
doi = {10.1111/petr.70084}
}
EUVIMED